Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia : Implications for Treatment Strategy
Joint Authors
Kuebler, J. Phillip
Provenzano, Joel D.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-07-10
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Myeloproliferative disorders are variable disorders, based on the genetic abnormality present and the cell line progenitors that are affected.
In this case, we discuss a novel gene translocation in the subset of PDGFRB mutations, first seen with prominent hyperbasophilia.
This case demonstrates the possibility for lower therapeutic doses of imatinib mesylate than previously reported, in order to control leukocyte counts and reverse the genetic mutation.
American Psychological Association (APA)
Provenzano, Joel D.& Kuebler, J. Phillip. 2013. Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia : Implications for Treatment Strategy. Case Reports in Hematology،Vol. 2013, no. 2013, pp.1-3.
https://search.emarefa.net/detail/BIM-492325
Modern Language Association (MLA)
Provenzano, Joel D.& Kuebler, J. Phillip. Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia : Implications for Treatment Strategy. Case Reports in Hematology No. 2013 (2013), pp.1-3.
https://search.emarefa.net/detail/BIM-492325
American Medical Association (AMA)
Provenzano, Joel D.& Kuebler, J. Phillip. Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia : Implications for Treatment Strategy. Case Reports in Hematology. 2013. Vol. 2013, no. 2013, pp.1-3.
https://search.emarefa.net/detail/BIM-492325
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-492325